COMMENTARY
Approval of Switch-OTC Epadel Puts Spotlight on Quality, Track Record of Pharmacists
A switch-OTC version of Mochida Pharmaceutical’s ethical hyperlipidemia treatment Epadel (ethyl icosapentate) is expected to be launched in the near future. It will be the first switch-OTC drug to be taken for long periods for a lifestyle disease. Once approved,…
To read the full story
COMMENTARY
- Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
March 11, 2026
- Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
March 10, 2026
- ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use
March 9, 2026
- G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands
February 25, 2026
- Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





